Decreased plasma concentrations of apolipoprotein M in sepsis and systemic inflammatory response syndromes

Critical Care

Volumn 16, Issue 2, 2012, Pages

  Kumaraswamy, Sunil B ^a   Linder, Adam ^a   Åkesson, Per ^a   Dahlbäck, Björn ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN M; C REACTIVE PROTEIN; CHOLESTEROL; HEPARIN BINDING PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LACTIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROCALCITONIN; APOLIPOPROTEIN; APOM PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN; LIPOCALIN;

ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; ADULT; BLOOD; CASE CONTROL STUDY; FEMALE; MALE; NONPARAMETRIC TEST; PROSPECTIVE STUDY;

ADULT; APOLIPOPROTEINS; APOLIPOPROTEINS B; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIPOCALINS; LIPOPROTEINS, HDL; MALE; PROSPECTIVE STUDIES; SEPSIS; STATISTICS, NONPARAMETRIC; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84859796110     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11305     Document Type: Article

References (40)

1. Dahlback B, Nielsen LB. Apolipoprotein M affecting lipid metabolism or just catching a ride with lipoproteins in the circulation?. Cell Mol Life Sci 2009, 66:559-564. 10.1007/s00018-009-8764-8, 19153651.
2. Xu N, Dahlback B. A novel human apolipoprotein (apoM). J Biol Chem 1999, 274:31286-31290. 10.1074/jbc.274.44.31286, 10531326.
3. Axler O, Ahnstrom J, Dahlback B. Apolipoprotein M associates to lipoproteins through its retained signal peptide. FEBS Lett 2008, 582:826-828. 10.1016/j.febslet.2008.02.007, 18279674.
4. Christoffersen C, Ahnstrom J, Axler O, Christensen EI, Dahlback B, Nielsen LB. The signal peptide anchors apolipoprotein M in plasma lipoproteins and prevents rapid clearance of apolipoprotein M from plasma. J Biol Chem 2008, 283:18765-18772. 10.1074/jbc.M800695200, 18460466.
5. Christoffersen C, Nielsen LB, Axler O, Andersson A, Johnsen AH, Dahlback B. Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res 2006, 47:1833-1843. 10.1194/jlr.M600055-JLR200, 16682745.
6. Axler O, Ahnstrom J, Dahlback B. An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma. J Lipid Res 2007, 48:1772-1780. 10.1194/jlr.M700113-JLR200, 17526892.
7. Duan J, Dahlback B, Villoutreix BO. Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site-directed mutagenesis. FEBS Lett 2001, 499:127-132. 10.1016/S0014-5793(01)02544-3, 11418126.
8. Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstrom J, Sevvana M, Egerer-Sieber C, Muller YA, Hla T, Nielsen LB, Dahlback B. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci USA 2011, 108:9613-9618. 10.1073/pnas.1103187108, 3111292, 21606363.
9. Sevvana M, Ahnstrom J, Egerer-Sieber C, Lange HA, Dahlback B, Muller YA. Serendipitous fatty acid binding reveals the structural determinants for ligand recognition in apolipoprotein M. J Mol Biol 2009, 393:920-936. 10.1016/j.jmb.2009.08.071, 19733574.
10. Blaho VA, Hla T. Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors. Chem Rev 2011, 111:6299-6320. 10.1021/cr200273u, 21939239.
11. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007, 115:84-105. 10.1016/j.pharmthera.2007.04.006, 17561264.
12. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S. Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 2009, 78:743-768. 10.1146/annurev.biochem.78.072407.103733, 19231986.
13. Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol 2011, 11:403-415. 10.1038/nri2974, 21546914.
14. Feingold KR, Shigenaga JK, Chui LG, Moser A, Khovidhunkit W, Grunfeld C. Infection and inflammation decrease apolipoprotein M expression. Atherosclerosis 2008, 199:19-26. 10.1016/j.atherosclerosis.2007.10.007, 18054359.
15. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340:448-454. 10.1056/NEJM199902113400607, 9971870.
16. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004, 45:1169-1196. 10.1194/jlr.R300019-JLR200, 15102878.
17. Murch O, Collin M, Hinds CJ, Thiemermann C. Lipoproteins in inflammation and sepsis. I. Basic science. Intensive Care Med 2007, 33:13-24. 10.1007/s00134-006-0432-y, 17093985.
18. Wendel M, Paul R, Heller AR. Lipoproteins in inflammation and sepsis. II. Clinical aspects. Intensive Care Med 2007, 33:25-35. 10.1007/s00134-006-0433-x, 17093984.
19. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006, 58:342-374. 10.1124/pr.58.3.1, 16968945.
20. Kitchens RL, Thompson PA, Munford RS, O'Keefe GE. Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. J Lipid Res 2003, 44:2339-2348. 10.1194/jlr.M300228-JLR200, 12923224.
21. Levels JH, Lemaire LC, van den Ende AE, van Deventer SJ, van Lanschot JJ. Lipid composition and lipopolysaccharide binding capacity of lipoproteins in plasma and lymph of patients with systemic inflammatory response syndrome and multiple organ failure. Crit Care Med 2003, 31:1647-1653. 10.1097/01.CCM.0000063260.07222.76, 12794399.
22. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011, 8:222-232. 10.1038/nrcardio.2010.222, 21304474.
23. Cohen J. The immunopathogenesis of sepsis. Nature 2002, 420:885-891. 10.1038/nature01326, 12490963.
24. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008, 34:17-60. 10.1007/s00134-007-0934-2, 2249616, 18058085.
25. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005, 365:63-78. 10.1016/S0140-6736(04)17667-8, 15639681.
26. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150. 10.1056/NEJMra021333, 12519925.
27. Barlage S, Gnewuch C, Liebisch G, Wolf Z, Audebert FX, Gluck T, Frohlich D, Kramer BK, Rothe G, Schmitz G. Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation. Intensive Care Med 2009, 35:1877-1885. 10.1007/s00134-009-1609-y, 19669126.
28. Berbee JF, van der Hoogt CC, de Haas CJ, van Kessel KP, Dallinga-Thie GM, Romijn JA, Havekes LM, van Leeuwen HJ, Rensen PC. Plasma apolipoprotein CI correlates with increased survival in patients with severe sepsis. Intensive Care Med 2008, 34:907-911. 10.1007/s00134-008-1006-y, 18231776.
29. Chenaud C, Merlani PG, Roux-Lombard P, Burger D, Harbarth S, Luyasu S, Graf JD, Dayer JM, Ricou B. Low apolipoprotein A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation. Crit Care Med 2004, 32:632-637. 10.1097/01.CCM.0000114820.47460.0A, 15090939.
30. Chien JY, Jerng JS, Yu CJ, Yang PC. Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med 2005, 33:1688-1693. 10.1097/01.CCM.0000171183.79525.6B, 16096442.
31. Grion CM, Cardoso LT, Perazolo TF, Garcia AS, Barbosa DS, Morimoto HK, Matsuo T, Carrilho AJ. Lipoproteins and CETP levels as risk factors for severe sepsis in hospitalized patients. Eur J Clin Invest 2010, 40:330-338. 10.1111/j.1365-2362.2010.02269.x, 20486994.
32. Vermont CL, den Brinker M, Kakeci N, de Kleijn ED, de Rijke YB, Joosten KF, de Groot R, Hazelzet JA. Serum lipids and disease severity in children with severe meningococcal sepsis. Crit Care Med 2005, 33:1610-1615. 10.1097/01.CCM.0000171272.50888.AD, 16003070.
33. Linder A, Christensson B, Herwald H, Bjorck L, Akesson P. Heparin-binding protein: an early marker of circulatory failure in sepsis. Clin Infect Dis 2009, 49:1044-1050. 10.1086/605563, 19725785.
34. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: the ACCP/SCCM Consensus Conference Committee, American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655. 10.1378/chest.101.6.1644, 1303622.
35. Rodriguez C, Gonzalez-Diez M, Badimon L, Martinez-Gonzalez J. Sphingosine-1-phosphate: bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thromb Haemost 2009, 101:665-673.
36. Elsoe S, Ahnstrom J, Christoffersen C, Hoofnagle AN, Plomgaard P, Heinecke JW, Binder CJ, Bjorkbacka H, Dahlback B, Nielsen LB. Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL. Atherosclerosis 2012, 221:91-7. 10.1016/j.atherosclerosis.2011.11.031, 22204862.
37. Mosialou I, Krasagakis K, Kardassis D. Opposite regulation of the human apolipoprotein M gene by hepatocyte nuclear factor 1 and Jun transcription factors. J Biol Chem 2011, 286:17259-17269. 10.1074/jbc.M110.200659, 3089568, 21454713.
38. Mosialou I, Zannis VI, Kardassis D. Regulation of human apolipoprotein M gene expression by orphan and ligand-dependent nuclear receptors. J Biol Chem 2010, 285:30719-30730. 10.1074/jbc.M110.131771, 2945566, 20660599.
39. Richter S, Shih DQ, Pearson ER, Wolfrum C, Fajans SS, Hattersley AT, Stoffel M. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 2003, 52:2989-2995. 10.2337/diabetes.52.12.2989, 14633861.
40. Memon RA, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. In vivo and in vitro regulation of sterol 27-hydroxylase in the liver during the acute phase response: potential role of hepatocyte nuclear factor-1. J Biol Chem 2001, 276:30118-30126. 10.1074/jbc.M102516200, 11406622.